欧林生物(688319.SH)：2025年度净利润2,223.17万元，同比增长7.10%

Core Viewpoint - Olin Bio (688319.SH) reported a revenue of 704 million yuan for the fiscal year 2025, marking a year-on-year growth of 19.58% [1] Financial Performance - The net profit attributable to the parent company's shareholders reached 22.23 million yuan, reflecting a year-on-year increase of 7.10% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 9.88 million yuan, showing a year-on-year decrease of 11.64% [1] Market Activity - The company has been actively enhancing market promotion, leading to steady growth in the sales of tetanus vaccine [1]